Navigation Links
Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
Date:11/30/2011

s. 

The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs.  Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs).  There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs."  Without a known ligand, drug development for a given receptor is extremely difficult.

Omeros uses its proprietary high-throughput CRA to identify small-molecule agonists and antagonists for orphan GPCRs, unlocking them to drug development.  Omeros believes that it is the first to possess the capability to unlock orphan GPCRs in high-throughput, and that currently there is no other comparable technology.  Unlocking these receptors could lead to the development of drugs that act at these new targets. T here is a broad range of indications linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system.  The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs.  Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market.  Behind its clinical ca
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
2. Omeros to Present at Two Upcoming Conferences
3. Omeros to Present at Future Leaders in the Biotech Industry Conference
4. Omeros to Present at Needham Healthcare Conference
5. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
6. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
7. Omeros Secures $40 Million Committed Equity Financing Facility
8. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
9. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
10. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
11. Omeros Commences Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... DES MOINES, Iowa (PRWEB) July 23, 2014 ... will join the business as vice president of Agricultural ... from Mendel Biotechnology where he served most recently as ... brings extensive biotechnology and business leadership in the seed ... DuPont Pioneer,” said Paul E. Schickler , president ...
(Date:7/23/2014)... 23, 2014 Shire plc ... global specialty biopharmaceutical company, and ArmaGen, a US ... licensing and collaboration agreement for AGT-182, an investigational ... of both the central nervous system (CNS) and ... II). This collaboration strengthens Shire,s rare disease pipeline ...
(Date:7/23/2014)... 2014 China Cord Blood Corporation (NYSE: CO ... provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, ... multi-product healthcare company catering to the mother and child segment, today ... across the PRC, Singapore , Hong ... , the Philippines and ...
(Date:7/23/2014)... MD (PRWEB) July 23, 2014 a2z ... and ChirpE Mobile App, AACC Pathfinder, in its ... offerings. AACC’s annual meeting is planned for July 29-31, ... the place to be to connect with global leaders ... lab management, and other areas of breaking science in ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
... May 26, 2010 , , ... - Study Data Shows ORMD-0801 Resulted in Glucose and C-Peptide Reduction , ... Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( ... study to assess the safety and pharmacodynamics,of five oral insulin formulations in healthy subjects," ...
... 26 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, ... & Research Center at the University of Texas ... (CTRC) has started patient enrolment in a U.S. Phase ... combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic ...
... LONDON , May 26 ... announces the issuance of United States patent ... Treatment of Cancer and Other Neovascularization Disease, by the ... patent, which deepens the Company,s diverse portfolio of RNA ...
Cached Biology Technology:Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 2Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 3Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial 2Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial 3Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial 4Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 2Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 3Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 4
(Date:7/23/2014)... BOSTON , July 23, 2014 ... and threat detection, announced today it has been named ... . The Market Guide replaces Gartner,s well-known Magic Quadrant ... Gartner categorized BioCatch as one of several vendors to ... biometric analysis will become a standard feature of at ...
(Date:7/23/2014)... -- The potential for clinical use of induced ... strategies has previously been hindered by the risk ... tumors. The ability to use etoposide treatment to ... of heart disease, specifically acute myocardial infarction, is ... and Development , a peer-reviewed journal from Mary ...
(Date:7/23/2014)... Springer will publish the International Journal of Fuzzy ... the Taiwan Fuzzy Systems Association (TFSA). The cooperation will ... the area of fuzzy research., The International Journal ... papers that deal with the theory, design and application ... extension theory systems ranging from hardware to software. Launched ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
... think a city would provide a good home for bats ... buildings. But researchers at the University of Calgary made the ... for these animals. "I was really surprised," says Dr. ... biological sciences at the University of Calgary and lead author ...
... CHAMPAIGN, lll. Blood clotting is a complicated business, ... to injury. In a new study, researchers report that they ... interaction that is vital to blood clotting. This interaction ... baffled scientists for decades. The study appears ...
... State University shows that so-called biodegradable products are likely ... are releasing a powerful greenhouse gas as they break ... utensils, are broken down in landfills by microorganisms that ... a paper describing the research and professor and head ...
Cached Biology News:Big city holds empty promise for bats 2Team solves decades-old molecular mystery linked to blood clotting 2Team solves decades-old molecular mystery linked to blood clotting 3Study: Biodegradable products may be bad for the environment 2
... description: self locking design in ice/water ... new product number, created to easily ... no availability yet, please order under ... contact customer service for assistance. ID ...
Membrane Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
This modular laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Configurations are available with vertical or horizontal flow; options include a wo...
Biology Products: